Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOSTER: Osimertinib +/- Bevacizumab in 2L EGFRm T790M NSCLC
NCT03133546Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- May 2017
- Primary completion
- Feb 2021
- Countries
- 6
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Started May 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03133546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133546.